COVID-19 Project Team: Difference between revisions

Jump to navigation Jump to search
 
Line 89: Line 89:
*[[User:Rina Ghorpade|Rina Ghorpade, M.B.B.S.]]
*[[User:Rina Ghorpade|Rina Ghorpade, M.B.B.S.]]
*[[User:Rija Gul|Rija Gul, M.B.B.S]]
*[[User:Rija Gul|Rija Gul, M.B.B.S]]
'''Infectious diseases and COVID-19'''
'''Infectious Diseases and COVID-19'''
* [[User:Zaida Obeidat|Zaida Obeidat, M.D.]]
* [[User:Zaida Obeidat|Zaida Obeidat, M.D.]]
* [[User:Syed rizvi|Syed Rizvi, M.B.B.S.]]
* [[User:Syed rizvi|Syed Rizvi, M.B.B.S.]]
'''[[COVID-19 medical therapy]]
'''[[COVID-19 Medical Therapy]]
* [[User:Sara Zand|Sara Zand, M.D.]]
* [[User:Sara Zand|Sara Zand, M.D.]]
'''[[COVID-19 other diagnostic studies]]
'''[[COVID-19 Other Diagnostic Studies]]
* [[User:Mandana Safakhah|Mandana Safakhah, M.D.]]
* [[User:Mandana Safakhah|Mandana Safakhah, M.D.]]
'''[[COVID-19 Vaccines]]'''
* [[User:Jose Loyola|José Eduardo Riceto Loyola Junior, M.D.]]

Latest revision as of 01:27, 24 August 2021

COVID-19 Project
Introduction
Team
Meetings' Summary
Topics
Ongoing Clinical Trials

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]

Meet The Team

Associate Editor(s)-in-Chief:

  • The name of the leaders are written in bold: